Mesenchymal Stromal Cells for ARDS (COVID positive and COVID negative)

Grant Award Details

Mesenchymal Stromal Cells for ARDS (COVID positive and COVID negative)

Grant Type: Clinical Trial Stage Projects

Grant Number: CLIN2COVID19-11823

Project Objective: To evaluate the safety and efficacy of allogeneic bone marrow- derived human mesenchymal stroll cells in COVID-19 positive patients in the conduct a Phase 2 b, randomized , double blind, placebo controlled multi center clinical trial for the treatment of Acute Respiratory Distress Syndrome.

Investigator:

Name:	Michael Matthay
Institution:	University of California, San Francisco
Type:	PI

Disease Focus: COVID-19, Infectious Disease

Human Stem Cell Use: Adult Stem Cell

Award Value: $701,049

Status: Pre-Active

Grant Application Details

Application Title: Mesenchymal Stromal Cells for ARDS (COVID positive and COVID negative)

Public Abstract:	**Therapeutic Candidate or Device** Novel testing of a cell based therapy (Mesenchymal Stromal Cells) for respiratory failure from ARDS. **Indication** COVID-19 positive or negative ARDS patients **Therapeutic Mechanism** It will hopefully improve oxygenation in ARDS patients and potentially decrease mortality. **Unmet Medical Need** There is an unmet need for more effective treatments for ARDS both COVID-19 positive and COVID-19 negative. **Project Objective** Improvement in respiratory function after ARDS **Major Proposed Activities** Assess clinical efficacy of MSC treatment for ARDS in this double-blind, randomized, placebo-controlled trial.
Statement of Benefit to California:	This new therapy could improve survival from ARDS, a major cause of acute respiratory failure in the citizens of California.

Source URL: https://www.cirm.ca.gov/our-progress/awards/mesenchymal-stromal-cells-ards-covid-positive-and-covid-negative